Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Sang Kim, Han; Ju Kwon, Hyeong; Jung, Inkyung; Ran Yun, Mi; Ahn, Myung‐Ju; Woog Kang, Byung; Sun, Jong‐Mu; Bae Kim, Sung; Yoon, Dok-Hyun; Uk Park, Keon; Lee, Se‐Hoon; Woo Koh, Yoon; Hoon Kim, Se; Chang Choi, Eun; Koo, Dong‐Hoe; Hee Sohn, Jin; Kim, Bomi; Kwon, Nak‐Jung; Yun, Hwan‐Jung; Goo Lee, Min; Hyun Lee, Ji; Kim, Tae‐Min; Ryun Kim, Hye; Hang Kim, Joo; Paik, Soonmyung; Chul Cho, Byoung

doi:10.1158/1078-0432.ccr-14-1756

Public

Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck

Published in Clinical Cancer Research • Nov 26, 2014

Authors:

Han Sang Kim

Hyeong Ju Kwon

Inkyung Jung

Abstract

PURPOSE: The goals of this study were to investigate the clinical activity, safety, and biomarkers of dacomitinib, an irreversible tyrosine kinase inhibitor of EGFR, HER2, and HER4, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). EXPERIMENTAL DESIGN: Patients...

Subject

Head and neck squamous-cell carcinoma

Medicine

Head and neck

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!